ArticleToxicology reports2023
Survival, growth, behavior, hematology and serum biochemistry of mice under different concentrations of orally administered amorphous silica nanoparticle.
Article in Toxicology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesoporous Silica Nanoparticles as Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silica nanoparticles (SiNPs) are used extensively in consumer products and biomedical research basically due to ease of production and low cost. However, insufficient literature is reported regarding the toxicity and biocompatibility of SiNPs. The present study aimed to investigate the potential role of amorphous SiNPs on survival, growth, behavioral alterations, hematology and serum biochemistry of mice at four concentrations (control, 50, 100 and 150 mg/kg/day) of an oral supplementation for a period of 3 months. Signs of toxicity (lethargy, nausea, coma, tremors, vomiting and diarrhea, etc.) were noted at 9:00 am and 9:00 pm (twice a day) and the body weight of each of these mice was measured every week. The data were subjected to mean, standard deviation (S.D). Moreover, One-Way Analysis of Variance (ANOVA) and Dunnett's test were applied for analysis of statistical significance between groups by using SPSS software, version 20. All the mice survived with minor alterations in behavior and no significant weight changes were observed during the stipulated time period. Complete blood count (CBC) analysis indicated non-significant (P ≥ 0.05) systemic dysfunctions of organ systems. However, there was elevation in the level of AST and ALT in the analysis of serum biochemistry, while the values of all other examined parameters were not-significant (P ≥ 0.05). The study concluded that orally administered large silica nanoparticles up to the dose level of 150 mg/kg/day are nontoxic for the in vivo use in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.